Outlook Therapeutics, Inc. (OTLK)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Lawrence A. Kenyon CPA | EVP, CFO, Interim CEO, Treasurer, Secretary & Director | 476.17k | -- | 1966 |
| Mr. Jeffrey Evanson | Chief Commercial Officer | 451.17k | -- | 1969 |
| Mr. Joel Prieve | Senior Vice President of Licensing and M&A | -- | -- | -- |
| Dr. Surendra Sharma M.D. | Senior Vice President of Medical Affairs | -- | -- | -- |
| Dr. Jennifer M. Kissner Ph.D. | Senior Vice President of Clinical Development & Regulatory Affairs | -- | -- | -- |
| Mr. Jedd Comiskey | Senior VP - Head of Europe | -- | -- | -- |
Outlook Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 23
Description
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Iselin, New Jersey.
Corporate Governance
Upcoming Events
August 12, 2025 at 12:30 PM UTC - August 18, 2025 at 12:30 PM UTC
Outlook Therapeutics, Inc. Earnings Date
Recent Events
March 26, 2025 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
March 5, 2025 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission